Comparison of the inhibitory effects of ApoB100 and tissue factor pathway inhibitor on tissue factor and the influence of lipoprotein oxidation

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 7, 1999, Pages 1784-1790

  Ettelaie, Camille ^a,b   Wilbourn, Barry R ^a   Adam, Jacqueline M ^a   James, Nicola J ^a   Bruckdorfer, K Richard ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

ApoB100; Arginine; Inhibition; LDL; Lysine; Oxidation; Tissue factor; Tissue factor pathway inhibitor

Indexed keywords

APOLIPOPROTEIN B100; LOW DENSITY LIPOPROTEIN; THROMBOPLASTIN;

ARTICLE; ATHEROSCLEROSIS; BLOOD CLOTTING; HEMOSTASIS; HUMAN; HUMAN CELL; LIPID OXIDATION; PRIORITY JOURNAL; THROMBOSIS;

EID: 0033042458     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.7.1784     Document Type: Article

References (42)

1. Broze GJ Jr. Tissue factor pathway inhibitor. Thromb Haemost. 1995;74: 90-93.
2. Rao LVM, Rapaport SI. Studies of a mechanism inhibiting the initiation of the extrinsic pathway of coagulation. Blood. 1987;69:645-651.
3. Sandset PM, Warn-Cramer BJ, Rao LVM, Maki SL, Rapaport SI. Deletion of extrinsic pathway inhibitor [EPI] sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: evidence supporting a physiologic role for EPI as a natural anticoagulant. Proc Natl Acad Sci U S A. 1991;88:708-712.
4. Carson SD. Plasma high density lipoproteins inhibit the activation of coagulation factor X by factor VIIa and tissue factor. FEBS Lett. 1981; 132:37-40.
5. Carson SD. Tissue factor (coagulation factor III) inhibition by apolipoprotein A-II. J Biol Chem. 1987;262:718-721.
6. Ettelaie C, Howell RM. The inhibition of thromboplastin by apolipoprotein B and the effect of various lipids. Thromb Res. 1992;68: 175-184.
7. Ettelaie C, Howell RM, Bruckdorfer KR. The effect of lipid peroxidation and lipolysis on the ability of lipoproteins to influence thromboplastin activity. Biochim Biophys Acta. 1995;1257:25-30.
8. Ettelaie C, James NJ, Wilbourn B, Adam JM, Naseem KM, Bruckdorfer KR. The mechanism of inhibition of factor III (thromboplastin) activity by apolipoprotein-B 100: protein-protein interactions. Arterioscler Thromb Vasc Biol. 1996;16:639-647.
9. Girard TS, Warren LA, Novotny WF, Likert KM, Brown SG, Miletich JP, Broze GJ. Functional significance of the Kunitz-type inhibitory domains of LACI. Nature. 1989;338:518-520.
10. Mast AE, Broze GJ Jr. Physiological concentrations of tissue factor pathway inhibitor do not inhibit prothrombinase. Blood. 1996;87: 1845-1850.
11. Broze GJ Jr, Lange GW, Duffin KL, MacPhil L. Heterogeneity of plasma tissue factor pathway inhibitor. Blood Coagul Fibrinolysis. 1994;5: 551-559.
12. Nordfang O, Bjorn SE, Valentin S, Nielsen LS, Wildgoose P, Beck TC, Hedner U. The C-terminus of tissue factor pathway inhibitor is essential to its anticoagulant activity. Biochemistry. 1991;30:10371-10376.
13. Wesselschmidt R, Likert KM, Girard TJ, Wun TC, Broze GJ. Tissue factor pathway inhibitor: the carboxy-terminus is required for optimal inhibition of factor Xa. Blood. 1992;79:2004-2010.
14. Broze GJ, Girard TJ, Novotny WF. Regulation of coagulation by a multivalent Kunitz-type inhibitor. Biochemistry. 1990;29:7539-7546.
15. Sanders NL, Bajaj SP, Zivelin A, Rapaport SI. Inhibition of tissue factor/factor Vila activity in plasma requires factor X and an additional plasma component. Blood. 1985;66:204-212.
16. Hansen J-B, Huseby N-E, Sandset PM, Svensson B, Lyngmo V, Nordøy A. Tissue factor pathway inhibitor and lipoproteins: evidence for association with and regulation by LDL in human plasma. Arterioscler Thromb. 1994;14:223-229.
17. Hansen J-B, Huseby KR, Huseby N-E, Sandset PM, Hansen TA, Nordøy A. Effect of cholesterol lowering on intravascular pools of TFPI and its anticoagulant potential in type II hypercholesterolaemia. Arterioscler Thromb Vasc Biol 1995;15:879-885.
18. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witzum JL. Modifications of low density lipoprotein that increase its atherogenecity. N Engl J Med. 1989;320:915-924.
19. Palinski W, Ylä-Herttula S, Rosenfeld ME, Butter SW, Socher SA, Parthasarathy S, Curtiss LK, Witzum JL. Arteriosclerosis. 1990;10: 325-335.
20. Ettelaie C, Haris PI, James NJ, Wilbourn B, Adam JM, Bruckdorfer KR. Alterations in the structure of apolipoprotein B-100 determine the behaviour of LDL towards thromboplastin. Biochim Biophys Acta. 1997; 1345:237-247.
21. Lesnik P, Dentan C, Vonica A, Moreau M, Chapman MJ. Tissue factor pathway inhibitor activity associated with LDL is inactivated by cell-and copper-mediated oxidation. Arterioscler Thromb Vasc Biol. 1995;15: 1121-1130.
22. Wun TC, Kretsmer KK, Girard TJ, Miletich JP, Broze GJ Jr. Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type domains. J Biol Chem. 1988;263:6001-6004.
23. Weber K, Osborn M. The reliability of molecular weight determinations by dodecyl sulfate polyacrylamide gel electrophoresis. J Biol Chem. 1969;244:4406-4412.
24. Naseem KM, Goodall AH, Bruckdorfer KR. Differential effects of native and oxidatively modified LDL on platelet function. Platelets. 1997;8: 163-173.
25. El-Saadani M, Esterbauer H, El-Sayed M, Goher M, Jürgens G. A spectrophotometric assay for lipid peroxides in serum lipoproteins using a commercially available reagent. J Lipid Res. 1989;30:627-630.
26. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680-681.
27. Novotny WF, Girard TJ, Miletich JP, Broze GJ Jr. Purification and characterization of the lipoprotein associated coagulation inhibitor from human plasma. J Biol Chem. 1989;264:18831-18837.
28. Broze GJ Jr, Miletich JP. Isolation of the tissue factor inhibitor produced by Hep G2 hepatoma cells. Proc Natl Acad Sci USA. 1987;84: 1886-1890.
29. Wilcheck W, Miron T. Immobilization of enzymes and affinity ligands onto agarose via stable and uncharged carbamate linkages. Biochem Int. 1982;4:629-635.
30. Sandset PM, Abildgaard U, Pettersen M. A sensitive assay of extrinsic coagulation pathway inhibitor in plasma and plasma fractions. Thromb Res. 1987;47:389-400.
31. Stark GR. Recent developments in chemical modification and sequential degradation of proteins. Adv Protein Chem. 1970;24:261-308.
32. Mills GL, Lane PA, Weech PK. In: Burdon RH, van Knippenberg PH, eds. A Guidebook to Lipoprotein Technique. New York, NY: Elsevier: 1984.
33. Kondo S, Kisiel W. Evidence that plasma lipoproteins inhibit the factor VIIa-tissue factor complex by a different mechanism than extrinsic pathway inhibitor. Blood. 1987;70:1947-1954.
34. Hansen J-B, Huseby KR, Huseby N-E, Ezben M, Nordøy A. Tissue factor pathway inhibitor in complex with low density lipoprotein isolated from human plasma does not possess anticoagulant function in tissue factor-induced coagulation in vitro. Thromb Res. 1997;85:413-425.
35. Ettelaie C, James NJ, Adam JM, Nicola KP, Wilbourn BR, Bruckdorfer KR. Identification of a domain in apolipoprotein B-100 that inhibitos the procoagulant activity of tissue factor. Biochem J. 1998; 333:433-438.
36. Ettelaie C, Wilbourn B, James NJ, Gleeson AM, Adam JM, Bruckdorfer KR. The inhibitory action of apolipoprotein B-100 towards thromboplastin arises from the receptor binding domain of this protein. Blood Coagul Fibrinolysis. 1996;7:7. Abstract.
37. 2+-induced oxidation in relation to changes in lipid composition. Biochem J. 1996;319:217-227.
38. Valentin S, Norfang O, Bregengaard C, Wildgoose P. Evidence that the C-terminus of tissue factor pathway inhibitor (TFPI) is essential for its in vitro and in vivo interaction with lipoproteins. Blood Coagul Fibrinolysis. 1993;34:713-720.
39. Novotny WF, Brown SG, Miletich JP, Radar DJ, Broze GJ Jr. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood. 1991;78:387-393.
40. Lindahl AK, Jacobsen PB, Sandset PM, Abildgaard U. Tissue factor pathway inhibitor with high anticoagulant activity is increased in post-heparin plasma and in plasma from cancer patients. Blood Coagul Fibrinolysis. 1991;2:713-721.
41. Novotny WF, Palmier M, Wun TC, Broze GJ Jr, Miletich JP. Purification and properties of heparin releasable lipoprotein-associated coagulation inhibitor. Blood. 1991;78:394-400.
42. Hatakeyama K, Asada Y, Marutsuka K, Sato Y, Kamikubo Y, Sumiyoshi A. Localization and activity of tissue factor in human aortic atherosclerotic lesion. Atherosclerosis. 1997;133:213-219.